Quick Overview: "We expect to finish enrollment of all 40 volunteers before the end of April," The under-the-radar biotech that roared more than 20 percent Monday on a big deal with AstraZeneca. Is there more room to run? This under-the-radar biotech roared nearly 10 percent on news of its Phase 3 study. Can the momentum continue? Jim Cramer ...
Inovio Pharmaceuticals Stock Offering Concerns - Detailed Overview & Context
"We expect to finish enrollment of all 40 volunteers before the end of April," The under-the-radar biotech that roared more than 20 percent Monday on a big deal with AstraZeneca. Is there more room to run? This under-the-radar biotech roared nearly 10 percent on news of its Phase 3 study. Can the momentum continue? Jim Cramer ... Inovio Pharmaceuticals,INVO STOCK ANALYSIS BUY OR SELL Get the FREE Report on the Top 5 Robotics
